Compare Salesforce Inc (CRM) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Enveric Biosciences Inc — how do they compare? Salesforce Inc trades at $168.17 (market cap $137.23B), while Enveric Biosciences Inc trades at $1.25 (market cap $5.32M). The key difference: Salesforce Inc is far larger — about 25795.1× Enveric Biosciences Inc's market cap, and Salesforce Inc pays a 1.05% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| CRM | ENVB | |
|---|---|---|
Market Cap | $137.23B | $5.32M |
Sector | Technology | Health |
52-Week High | $270.25 | $17.40 |
52-Week Low | $150.12 | $1.28 |
Enterprise Value | $167.28B | $408.82K |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.22, up 4.84% today, showing strong momentum despite recent sector volatility. The stock demonstrates robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected), impressive 77.64% gross margins, and accelerating revenue growth to $37.9B in 2025. Technical indicators show bullish momentum with the current price near pivot point resistance at $170, while analyst consensus remains strongly positive with a $235.90 price target.
The outlook remains favorable given Salesforce's dominant market position, AI-driven growth initiatives, and improving profitability. Key risks include sector-wide software selloffs, AI competition, and macroeconomic sensitivity. With 76.84% analyst buy ratings and strong institutional support, the stock appears undervalued relative to growth prospects despite near-term volatility concerns.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
